DBV Technologies S.A. (DBV.PA)
EUR 0.61
(1.17%)
EUR 0.61
(1.17%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 38.74 Million USD | -25.49% |
| 2022 | 52 Million USD | 9.59% |
| 2021 | 47.44 Million USD | -28.92% |
| 2020 | 66.75 Million EUR | -14.76% |
| 2019 | 78.31 Million EUR | 35.67% |
| 2018 | 57.72 Million EUR | 0.48% |
| 2017 | 57.44 Million EUR | 22.33% |
| 2016 | 46.95 Million EUR | 102.57% |
| 2015 | 23.18 Million EUR | 91.21% |
| 2014 | 12.12 Million EUR | 50.31% |
| 2013 | 8.06 Million EUR | 60.43% |
| 2012 | 5.02 Million EUR | -3.37% |
| 2011 | 5.2 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 35.09 Million EUR | 10.21% |
| 2024 Q1 | 34.24 Million USD | -20.0% |
| 2023 Q2 | 53.27 Million USD | -1.03% |
| 2023 Q1 | 53.83 Million USD | 3.4% |
| 2023 FY | 38.74 Million USD | -25.49% |
| 2023 Q4 | 42.79 Million USD | -6.54% |
| 2023 Q3 | 45.79 Million USD | -14.05% |
| 2022 FY | 52 Million USD | 9.59% |
| 2022 Q4 | 52.06 Million USD | 44.36% |
| 2022 Q1 | 35.51 Million USD | -25.14% |
| 2022 Q2 | 40.56 Million USD | 14.2% |
| 2022 Q3 | 36.06 Million USD | -11.09% |
| 2021 Q2 | 57.56 Million USD | 10.22% |
| 2021 Q1 | 52.22 Million USD | -21.76% |
| 2021 Q3 | 54.03 Million USD | -6.14% |
| 2021 Q4 | 47.44 Million USD | -12.18% |
| 2021 FY | 47.44 Million USD | -28.92% |
| 2020 Q4 | 66.75 Million EUR | 0.0% |
| 2020 Q2 | 84.8 Million EUR | 0.0% |
| 2020 FY | 66.75 Million EUR | -14.76% |
| 2019 Q4 | 78.31 Million EUR | 4.57% |
| 2019 Q2 | 79.97 Million EUR | 0.0% |
| 2019 Q3 | 74.88 Million EUR | -6.35% |
| 2019 FY | 78.31 Million EUR | 35.67% |
| 2018 FY | 57.72 Million EUR | 0.48% |
| 2018 Q4 | 57.72 Million EUR | 0.0% |
| 2018 Q2 | 52.42 Million EUR | 0.0% |
| 2017 Q2 | 52.88 Million EUR | 0.0% |
| 2017 Q4 | 57.44 Million EUR | 0.0% |
| 2017 FY | 57.44 Million EUR | 22.33% |
| 2016 Q4 | 46.95 Million EUR | 0.0% |
| 2016 FY | 46.95 Million EUR | 102.57% |
| 2016 Q2 | 41.79 Million EUR | 0.0% |
| 2015 Q4 | 23.18 Million EUR | 0.0% |
| 2015 Q2 | 14.99 Million EUR | 0.0% |
| 2015 FY | 23.18 Million EUR | 91.21% |
| 2014 Q2 | 9.88 Million EUR | 0.0% |
| 2014 Q4 | 12.12 Million EUR | 0.0% |
| 2014 FY | 12.12 Million EUR | 50.31% |
| 2013 FY | 8.06 Million EUR | 60.43% |
| 2013 Q4 | 8.06 Million EUR | 0.0% |
| 2013 Q2 | 6.91 Million EUR | 0.0% |
| 2012 Q4 | 5.02 Million EUR | 0.0% |
| 2012 FY | 5.02 Million EUR | -3.37% |
| 2012 Q2 | 3.3 Million EUR | 0.0% |
| 2011 Q4 | 5.2 Million EUR | 0.0% |
| 2011 FY | 5.2 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -460.551% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 70.435% |
| Adocia SA | 31.87 Million EUR | -21.573% |
| Aelis Farma SA | 13.08 Million EUR | -196.218% |
| Biophytis S.A. | 15.84 Million EUR | -144.465% |
| Advicenne S.A. | 24.37 Million EUR | -58.942% |
| genOway Société anonyme | 14.45 Million EUR | -167.957% |
| IntegraGen SA | 5.97 Million EUR | -547.937% |
| Medesis Pharma S.A. | 6.42 Million EUR | -502.929% |
| Neovacs S.A. | 3.71 Million EUR | -943.75% |
| NFL Biosciences SA | 3.62 Million EUR | -970.11% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -471.266% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -1070.515% |
| Sensorion SA | 13.22 Million EUR | -192.92% |
| Theranexus Société Anonyme | 5.01 Million EUR | -672.405% |
| TME Pharma N.V. | 2.78 Million EUR | -1291.214% |
| Valbiotis SA | 13.7 Million EUR | -182.647% |
| TheraVet SA | 1.48 Million EUR | -2509.124% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | -89.297% |
| argenx SE | 402.79 Million EUR | 90.381% |
| BioSenic S.A. | 32.26 Million EUR | -20.088% |
| Celyad Oncology SA | 9.97 Million EUR | -288.307% |
| Galapagos NV | 1.56 Billion EUR | 97.519% |
| Genfit S.A. | 105.92 Million EUR | 63.421% |
| GeNeuro SA | 20.13 Million EUR | -92.381% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | -349.899% |
| Innate Pharma S.A. | 132.29 Million EUR | 70.712% |
| Inventiva S.A. | 101.59 Million EUR | 61.862% |
| MaaT Pharma SA | 22.46 Million EUR | -72.47% |
| MedinCell S.A. | 77.77 Million EUR | 50.18% |
| Nanobiotix S.A. | 95.74 Million EUR | 59.531% |
| Onward Medical N.V. | 25.69 Million EUR | -50.772% |
| Oryzon Genomics S.A. | 25.12 Million EUR | -54.207% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | 34.418% |
| Oxurion NV | 19.73 Million EUR | -96.318% |
| Pharming Group N.V. | 228.28 Million EUR | 83.028% |
| Poxel S.A. | 53.9 Million EUR | 28.118% |
| GenSight Biologics S.A. | 34.72 Million EUR | -11.571% |
| Transgene SA | 26.51 Million EUR | -46.115% |
| Financière de Tubize SA | 123.65 Million EUR | 68.665% |
| UCB SA | 6.56 Billion EUR | 99.41% |
| Valneva SE | 341.14 Million EUR | 88.643% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -752.107% |